Phase 2
N=389
Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
Coronary Disease · Heart Diseases · Cardiovascular Diseases · Neurologic Manifestations
Bottom Line
View on ClinicalTrials.gov: NCT00041392 ↗Enrolled (actual)
389
Serious AEs
17.7%
Results posted
Oct 2012
Primary outcome: Primary: Cognitive Function — 0.07; 0.12 Continuous cognitive change score
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Magnesium (Drug); 0.9% saline (Drug)
- Age
- Adult, Older Adult · 55+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cognitive Function |
0.07; 0.12 | — |
Summary
The purpose of this study is to examine the effects of supplemental magnesium on the neurocognitive function of individuals undergoing coronary artery bypass graft (CABG) surgery.
Eligibility Criteria
Inclusion Criteria
- Coronary heart disease
Exclusion Criteria
- Early dementia
- History of psychiatric illness
Data sourced from ClinicalTrials.gov (NCT00041392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.